Home › Research › Treatments
Before the bolus: why anti-amyloid therapy must become part of every stroke code
Khaliq AS, Khan K.. Annals of medicine and surgery (2012), 2026-08-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Anti-amyloid monoclonal antibodies provide disease-modifying treatment options for selected patients with early symptomatic Alzheimer disease, but introduce new challenges for acute stroke care. Amyloid-related imaging abnormalities (ARIA) are often asymptomatic; however, symptomatic ARIA may cause aphasia, focal weakness, visual disturbance, confusion, headache, or seizures, and can resemble acute ischemic stroke. Initial noncontrast computed tomography may be nondiagnostic in both conditions, and failure to identify anti-amyloid exposure can complicate time-sensitive reperfusion decisions. Current regulatory guidance advises caution when considering thrombolytic therapy because serious and fatal intracerebral hemorrhage has been reported, although the absolute risk and a safe interval following anti-amyloid administration remain uncertain. Conversely, attributing every acute neurological deficit to ARIA could delay effective reperfusion for a true ischemic stroke. This editorial examines the clinical and imaging features relevant to this diagnostic overlap and proposes a systems-based response involving reliable medication identification, rapid vascular imaging, targeted magnetic resonance imaging, specialist collaboration, and separate consideration of intravenous thrombolysis and mechanical thrombectomy. Anti-amyloid exposure should be recognized as time-critical information during stroke evaluation. The objective is not automatic exclusion from reperfusion, but an individualized approach that minimizes avoidable hemorrhagic harm while preserving appropriate treatment for confirmed cerebral ischemia.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Khaliq, A. S., & Khan, K. (2026). Before the bolus: why anti-amyloid therapy must become part of every stroke code. Annals of medicine and surgery (2012). https://doi.org/10.1097/ms9.0000000000005585
Vancouver
Khaliq AS, Khan K. Before the bolus: why anti-amyloid therapy must become part of every stroke code. Annals of medicine and surgery (2012). 2026. doi:10.1097/ms9.0000000000005585. PMID: 42725220.
BibTeX
@article{khaliq2026-42725220,
author = {Khaliq, A. S. and Khan, K.},
title = {{Before the bolus: why anti-amyloid therapy must become part of every stroke code}},
journal = {Annals of medicine and surgery (2012)},
year = {2026},
doi = {10.1097/ms9.0000000000005585},
pmid = {42725220},
url = {https://doi.org/10.1097/ms9.0000000000005585}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Current regulatory guidance advises caution when considering thrombolytic therapy because serious and fatal intracerebral hemorrhage has been reported, although the absolute risk and a safe interval following anti-amyloid administration remain uncertain.
- Conversely, attributing every acute neurological deficit to ARIA could delay effective reperfusion for a true ischemic stroke.
- This editorial examines the clinical and imaging features relevant to this diagnostic overlap and proposes a systems-based response involving reliable medication identification, rapid vascular imaging, targeted magnetic resonance imaging, specialist collaboration, and separate consideration of intravenous thrombolysis and mechanical thrombectomy.
- Anti-amyloid exposure should be recognized as time-critical information during stroke evaluation.
- The objective is not automatic exclusion from reperfusion, but an individualized approach that minimizes avoidable hemorrhagic harm while preserving appropriate treatment for confirmed cerebral ischemia.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 27 of the 58 points we could judge it on, which is 47 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Annals of medicine and surgery (2012)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42725220) |
| Free to read | 2 / 2 | Free to read |
| Points | 27 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 27 of the 58 points we could judge it on is 47 out of 100. |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “part”
5 studies in the library carry the topic tag “part”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.